Regeneron Pharmaceuticals (REGN) Share-based Compensation Growth (5y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.48% |
| Dec 31, 2025 | 15.46% |
| Sep 30, 2025 | 18.55% |
| Jun 30, 2025 | 19.45% |
| Mar 31, 2025 | 19.30% |
| Dec 31, 2024 | 17.92% |
| Sep 30, 2024 | 13.96% |
| Jun 30, 2024 | 16.10% |
| Mar 31, 2024 | 16.35% |
| Dec 31, 2023 | 13.67% |
| Sep 30, 2023 | 12.83% |
| Jun 30, 2023 | 13.59% |
| Mar 31, 2023 | 23.70% |
| Dec 31, 2022 | 12.78% |
| Sep 30, 2022 | 5.86% |
| Jun 30, 2022 | 5.68% |
| Mar 31, 2022 | 4.52% |
| Dec 31, 2021 | 4.04% |
| Sep 30, 2021 | 0.83% |
| Jun 30, 2021 | 2.01% |
| Mar 31, 2021 | -1.65% |
| Dec 31, 2020 | -5.17% |
| Sep 30, 2020 | -0.27% |
| Jun 30, 2020 | 1.89% |
| Mar 31, 2020 | 0.39% |
| Dec 31, 2019 | 3.39% |
| Sep 30, 2019 | 11.45% |
| Jun 30, 2019 | 10.29% |
| Mar 31, 2019 | 7.32% |
| Dec 31, 2018 | 11.92% |
| Sep 30, 2018 | 19.51% |
| Jun 30, 2018 | 19.17% |
| Mar 31, 2018 | 9.21% |
| Dec 31, 2017 | 32.81% |
| Sep 30, 2017 | 43.53% |
| Jun 30, 2017 | 43.97% |
| Mar 31, 2017 | 41.91% |
| Dec 31, 2016 | 58.34% |
| Sep 30, 2016 | 57.95% |
| Jun 30, 2016 | 60.42% |
| Mar 31, 2016 | 57.24% |
| Dec 31, 2015 | 63.48% |
| Sep 30, 2015 | 63.47% |
| Jun 30, 2015 | 61.02% |
| Mar 31, 2015 | 63.67% |
| Dec 31, 2014 | 67.17% |
| Sep 30, 2014 | 55.43% |